Table III.
Baseline characteristics of patients hospitalized with SARS-CoV-2
| Characteristics | Total, N = 281 | Clinical group |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Respiratory, N = 143 | MIS-C, N = 69 | Other, N = 69 | P value | ||||||
| Age, y | |||||||||
| Median age, y (IQR) | 10 | (1-17) | 14 | (3-19) | 7 | (3-11) | 7 | (0-16) | <.001 |
| Sex | |||||||||
| Male | 170/281 | (60.5%) | 87/143 | (60.8%) | 42/69 | (60.9%) | 41/69 | (59.4%) | .99 |
| Race/ethnicity | |||||||||
| Hispanic | 125/245 | (51.0%) | 70/120 | (58.3%) | 27/65 | (41.5%) | 28/60 | (46.7%) | .040 |
| Non-Hispanic black | 57/245 | (23.3%) | 21/120 | (17.5%) | 23/65 | (35.4%) | 13/60 | (21.7%) | |
| Non-Hispanic white | 49/245 | (20.0%) | 25/120 | (20.8%) | 9/65 | (13.8%) | 15/60 | (25.0%) | |
| Non-Hispanic other | 14/245 | (5.7%) | 4/120 | (3.3%) | 6/65 | (9.2%) | 4/60 | (6.7%) | |
| Insurance | |||||||||
| Private | 72/281 | (25.6%) | 32/143 | (22.4%) | 28/69 | (40.6%) | 12/69 | (17.4%) | .039 |
| Medicaid/Medicare | 188/281 | (66.9%) | 97/143 | (67.8%) | 38/69 | (55.1%) | 53/69 | (76.8%) | |
| Uninsured/self-pay | 5/281 | (1.8%) | 3/143 | (2.1%) | 1/69 | (1.4%) | 1/69 | (1.4%) | |
| Other/unknown | 16/281 | (5.7%) | 11/143 | (7.7%) | 2/69 | (2.9%) | 3/69 | (4.3%) | |
| SES by ZIP code | |||||||||
| Low SES∗ | 87/281 | (31.0%) | 47/143 | (32.9%) | 21/69 | (30.4%) | 19/69 | (27.5%) | .75 |
| Coexisting conditions | |||||||||
| Obesity∗ | 85/250 | (34.0%) | 62/134 | (46.3%) | 18/64 | (28.1%) | 5/52 | (9.6%) | <.001 |
| Respiratory∗ | 49/281 | (17.4%) | 39/143 | (27.3%) | 6/69 | (8.7%) | 4/69 | (5.8%) | <.001 |
| Neurologic∗ | 23/281 | (8.2%) | 22/143 | (15.4%) | 0/69 | (0.0%) | 1/69 | (1.4%) | <.001 |
| Immunosuppressed∗ | 16/281 | (5.7%) | 13/143 | (9.1%) | 1/69 | (1.4%) | 2/69 | (2.9%) | .052 |
| Diabetes∗ | 11/281 | (3.9%) | 8/143 | (5.6%) | 0/69 | (0.0%) | 3/69 | (4.3%) | .14 |
| Sickle cell | 9/281 | (3.2%) | 7/143 | (4.9%) | 2/69 | (2.9%) | 0/69 | (0.0%) | .21 |
| Cardiovascular∗ | 18/281 | (6.4%) | 12/143 | (8.4%) | 2/69 | (2.9%) | 4/69 | (5.8%) | .30 |
| Gastrointestinal∗ | 10/281 | (3.6%) | 10/143 | (7.0%) | 0/69 | (0.0%) | 0/69 | (0.0%) | .005 |
| History of smoking∗ | 13/228 | (5.7%) | 10/116 | (8.6%) | 0/52 | (0.0%) | 3/60 | (5.0%) | .069 |
| Medical complexity∗ | 59/281 | (21.0%) | 45/143 | (31.5%) | 5/69 | (7.2%) | 9/69 | (13.0%) | <.001 |
| COVID-19 testing | |||||||||
| Only RT-PCR+ | 204/281 | (72.6%) | 133/143 | (93.0%) | 10/69 | (14.5%) | 61/69 | (88.4%) | <.001 |
| Only IgG+ | 44/281 | (15.7%) | 3/143 | (2.1%) | 36/69 | (52.2%) | 5/69 | (7.2%) | |
| Both PCR+ and IgG+ | 20/281 | (7.1%) | 7/143 | (4.9%) | 10/69 | (14.5%) | 3/69 | (4.3%) | |
| Only exposure | 13/281 | (4.6%) | 0/143 | (0.0%) | 13/69 | (18.8%) | 0/69 | (0.0%) | |
| Vital signs on admission | |||||||||
| O2 saturation <90% | 16/281 | (5.7%) | 16/143 | (11.2%) | 0/69 | (0.0%) | 0/69 | (0.0%) | <.001 |
| Tachypnea for age∗ | 66/281 | (23.5%) | 47/143 | (32.9%) | 18/69 | (26.1%) | 1/69 | (1.4%) | <.001 |
| Admission laboratory test results, median (IQR) | |||||||||
| Hemoglobin, g/dL | 12.1, n = 270 | (10.8-13.8) | 12.7, n = 137 | (10.9-14.5) | 11.4, n = 69 | (10.4-12.2) | 12.6, n = 64 | (11.5-13.95) | <.001 |
| WBC, × 109/L | 9.0, n = 272 | (6.2-14.2) | 8.5, n = 138 | (5.6-12.6) | 9.8, n = 69 | (7.4-14.6) | 9.8, n = 65 | (6.4-14.9) | .051 |
| Absolute neutrophil count, × 109/L | 5.8, n = 269 | (3.3-9.6) | 5.1, n = 137 | (2.7-8.9) | 7.6, n = 69 | (5.6-11.1) | 5.1, n = 63 | (2.6-9.8) | <.001 |
| Absolute lymphocyte count, × 109/L | 1.6, n = 269 | (0.9-2.7) | 1.5, n = 137 | (0.9-2.65) | 1.3, n = 69 | (0.8-1.9) | 2.1, n = 63 | (1.4-3.4) | <.001 |
| Platelets, × 109/L | 231, n = 270 | (164-346) | 233, n = 137 | (178-342) | 164, n = 69 | (112-287) | 301 n = 64 | (215-412) | <.001 |
| Alanine aminotransferase, U/L | 29.0, n = 247 | (18-55) | 31.5, n = 128 | (18.5-58) | 38.0, n = 67 | (22-64) | 20.0, n = 52 | (16-26) | <.001 |
| CRP, mg/dL | 7.8, n = 207 | (1.73-27.2) | 4.5, n = 104 | (1.0-14.5) | 25.7, n = 67 | (10-38.1) | 3.5, n = 36 | (0.5-7.9) | <.001 |
| Coinfections | |||||||||
| Viral infections | 12/281 | (4.3%) | 6/143 | (4.2%) | 3/69 | (4.3%) | 3/69 | (4.3%) | 1.00 |
| Chest radiograph findings | |||||||||
| Bilateral infiltrates | 71/215 | (33.0%) | 63/143 | (49.2%) | 8/69 | (12.7%) | 0/24 | (0.0%) | <.001 |
RT, reverse transcriptase; WBC, white blood cell.
Data are presented as n/total (%) for categorical measures and median (IQR) for continuous measures. Pairwise comparison between groups are shown in Table VI. Continuous variables are compared using ANOVA or Kruskal–Wallis based on normality test, categorical variables are compared using Fisher exact tests.
∗
See definitions in Table II.